Professional Documents
Culture Documents
www. AJOG.org
GENERAL GYNECOLOGY
board stopped the treatment arm as it was adding risk with no further
benefit to the patients. An observational cohort with additional 75 cases
was followed up in the no treatment arm and no failure was identified
(probability of an adverse event, 0%; 95% confidence interval,
0 0.03).
with uncomplicated septic abortion were treated with intravenous antibiotics, followed by uterine evacuation. On hospital discharge (day 1),
patients were randomized to receive either oral doxycycline plus metronidazole or placebo, until completing 10 days of treatment. Clinical cure
was defined by the absence of fever (37.7C), reduced vaginal bleeding, and minimal or no pelvic pain.
not be necessary.
Key words: antibiotics, doxycycline, metronidazole, septic abortion
Cite this article as: Savaris RF, Moraes GS, Cristovam RA, et al. Are antibiotics necessary after 48 hours of improvement in infected/septic abortions? A
randomized controlled trial followed by a cohort study. Am J Obstet Gynecol 2011;204:301.e1-5.
pelvic inflammatory disease by the Centers for Disease Control and Prevention
(CDC).6
Contrary to prolonged treatment with
oral antibiotics, French and Smaill7 demonstrated that it is unnecessary to continue antibiotic therapy in postcesarean
section endometritis once the patient is
afebrile for 48 hours. It could be safe and
less expensive to utilize this regimen in
cases of uncomplicated septic abortion.
There is no evidence thus far to show that
this shorter regimen is safe in such cases.
The objective of this is study was to
investigate the need for oral antibiotics
after 48 hours of clinical improvement,
in patients with uncomplicated septic
abortion who have undergone uterine
evacuation and received a minimum of
48 hours of intravenous antibiotics.
301.e1
Research
General Gynecology
www.AJOG.org
Outcome
At 48-72 hours after hospital discharge,
patients were contacted by telephone to
determine their clinical condition. After
finishing the outpatient treatment (day
10), patients were seen by one of the investigators (G.S.M., R.A.C.). Adherence
to the study protocol was evaluated by
examining the medication packets. At
this visit, a standard interview was utilized to identify the presence or absence
of the primary outcome (clinical cure).
Clinical cure was defined as the absence
of fever (37.8C), reduced vaginal
bleeding, and minimal or no pelvic
pain. Clinical failure was defined as hospital readmission, presence of fever
(37.8C) after hospital discharge, no
reduction of vaginal bleeding, persistence of pelvic pain, or the need to use
additional medication (antibiotics or
pain medication) whether prescribed or
not.
FIGURE
Sample size
Sample size for equivalence was calculated according to Blackwelder,9 using
the formula:
n
Savaris. Antibiotics in infected/septic abortions. Am J Obstet Gynecol 2011.
Intervention
Before hospital discharge, patients were
invited to participate in the study (day
1). Those meeting study criteria and providing consent were randomized to receive either oral doxycycline 100 mg
twice daily plus metronidazole 250 mg
twice a day, or an identical placebo, until
completion of 10 days of treatment (day
10). Medications were prepared by the
pharmacy of the Hospital de Clnicas de
Porto Alegre, in identical coded blister
packets and capsules to assure double
blinding. Patients were instructed not to
use drugs for pain or fever. They were
instructed to return to the hospital if they
experienced pain or fever.
Z Z2 PS1 PS PT1 PT
PS PT d2
where n the sample size for each treatment group; Z the standard normal
variate corresponding to the significance level, ie, an error of 0.02 2.326;
Z the standard normal variate corresponding to the tail probability of size ,
ie, error of 0.1 1.2816; and d the
difference between the conventional (PS)
and short (PT) treatment effects that is
considered to be clinically meaningful,
herein 10%. In antiinfective studies, a
d of 10% was chosen as recommended by
the US Food and Drug Administration.10 Based on our local experience,
and hospital electronic records, rate of
cures with long antibiotic protocol is
near 99%. The estimated rate of clinical
cure with placebo treatment was 97%.
These figures yield a minimum of 79 patients in each group (conventional and
short treatment).
Interim analysis was planned a priori
and calculated according to Fang,11 con-
General Gynecology
www.AJOG.org
sidering 2 stages of analysis. The adjusted
critical Z value (derived from adjusted
for 0.05, and of 0.1) was considered
in a scenario where the rate of cure for
the standard intervention is 100% and
for the placebo is 80% (chosen arbitrarily) for possible early stopping. If a
higher rate of cure in the placebo and in
the antibiotic group was observed, eg,
100%, the use of antibiotics would give
no additional benefit for the patients,
and the study should be stopped. These
figures suggested that the first interim
analysis should be with 27 patients per
group, in each stage, yielding a total of
108 patients, ie, 27 2 groups 2 stages.
If the study was stopped due to a high
rate of cure in the placebo arm (eg,
100%), an observational cohort would
be carried out until reaching at least the
initial sample size calculated for the placebo arm.
Observational cohort
In the observational cohort, the same inclusion and exclusion criteria, followup, and outcome assessment used in the
randomized clinical trial were applied.
Research
TABLE 1
Characteristic
Placebo
(n 28)
Doxycycline plus
metronidazole
(n 28)
28.2 7.7
25.9 6.2
..............................................................................................................................................................................................................................................
Ethnicity, n
.....................................................................................................................................................................................................................................
Caucasian
16
15
Afro-Brazilian
12
13
.....................................................................................................................................................................................................................................
..............................................................................................................................................................................................................................................
3.2 1.1
3.0 0.9
2.6 0.8
3.0 1.0
Pus in cervix, n
11
14
14
12
..............................................................................................................................................................................................................................................
..............................................................................................................................................................................................................................................
..............................................................................................................................................................................................................................................
..............................................................................................................................................................................................................................................
..............................................................................................................................................................................................................................................
..............................................................................................................................................................................................................................................
..............................................................................................................................................................................................................................................
..............................................................................................................................................................................................................................................
..............................................................................................................................................................................................................................................
..............................................................................................................................................................................................................................................
..............................................................................................................................................................................................................................................
Randomization
After signing the informed consent,
treatment allocation was dispensed according to a computer-generated randomization list, grouped in blocks of 4.
The allocation list was concealed until
interventions were assigned and coded.
The treatment assignment was then
communicated, via telephone, from a
central location. All study personnel and
participants were blinded to treatment
assignment for the duration of the study.
Treatment was given by one of the authors (G.S.M. or R.A.C.).
Statistical methods and ethical issues
Fisher exact test and descriptive analysis
were used for statistical analysis. The
outcome was analyzed using rates of cure
in intention to treat and per protocol
with 95% confidence intervals (CIs). For
0 events, ie, 100% of cure, the method of
Hanley and Lippman-Hand12 of probability for 95% CI was used. The following
formula was applied: (3/n), where n
number of cases in the group with 0
events. Adherence included exposure to
Oliguria, n
16
18
..............................................................................................................................................................................................................................................
Fever (37.8C), n
..............................................................................................................................................................................................................................................
R ESULTS
From May 2006 through November
2007, 60 patients with a diagnosis of septic abortion were admitted to Hospital
de Clnicas de Porto Alegre. Of these, 56
were eligible for the study and were randomized. The Figure depicts details of
the randomization. In November 2007,
the first interim analysis was conducted
on 56 patients. There were no clinical
failures in either arm (absolute risk difference, 0; 95% CI, 0.0 0.1). Characteristics of the sample before randomization are in Table 1. A woman from the
placebo group, who returned the medication without taking it, constituted the
only protocol violation. She had a clinical cure. There were no serious adverse
events experienced by any patient after
hospital discharge. Furthermore, 28 pa-
301.e3
Research
General Gynecology
www.AJOG.org
TABLE 2
Observational
(n 75)
27 6.19
..............................................................................................................................................................................................................................................
Ethnicity, n
.....................................................................................................................................................................................................................................
Caucasian
54
Afro-Brazilian
21
.....................................................................................................................................................................................................................................
..............................................................................................................................................................................................................................................
3.2 2.3
3.2 2.3
Pus in cervix, n
..............................................................................................................................................................................................................................................
..............................................................................................................................................................................................................................................
..............................................................................................................................................................................................................................................
..............................................................................................................................................................................................................................................
..............................................................................................................................................................................................................................................
..............................................................................................................................................................................................................................................
52
..............................................................................................................................................................................................................................................
a
..............................................................................................................................................................................................................................................
..............................................................................................................................................................................................................................................
Oliguria, n
..............................................................................................................................................................................................................................................
..............................................................................................................................................................................................................................................
..............................................................................................................................................................................................................................................
Fever (37.8C), n
30
..............................................................................................................................................................................................................................................
C OMMENT
All (100%) of the 103 patients with
uncomplicated infected/septic abortion
treated with intravenous antibiotics fol301.e4
www.AJOG.org
To our knowledge, this is the first report pertaining to the non-use of antibiotics, after hospital discharge, in patients
with uncomplicated septic abortion.
Hence we are unable to draw any comparison with other studies. Since the
point of entry into the study was at hospital discharge, the average stay in hospital for both groups was 3 days. In light of
our results, we have stopped giving antibiotics to patients with uncomplicated
septic abortion after 48 hours of clinical
improvement.
This trial questions the need for long
periods of treatment with oral antibiotics after clinical improvement in patients
with uncomplicated septic abortion. It
should be used as a reference for further
research.
f
REFERENCES
1. Singh S. Hospital admissions resulting from
unsafe abortion: estimates from 13 developing
countries. Lancet 2006;368:1887-92.
General Gynecology
2. Goldman LA, Garcia SG, Diaz J, Yam EA.
Brazilian obstetrician-gynecologists and abortion: a survey of knowledge, opinions and practices. Reprod Health 2005;2:10.
3. Stubblefield PG, Grimes DA. Septic abortion.
N Engl J Med 1994;331:310-4.
4. Brasil Ministrio da Sade. Abortamento infectado. In: Brasil Ministrio da Sade, ed.
Urgncias e emergncias maternas: guia para
diagnstico e conduta em situaes de risco
de morte materna. Braslia: MS/FEBRASGO;
2000:13.
5. World Health Organization. Managing complications in pregnancy and childbirth: a guide
for midwives and doctors. Geneva: WHO; 1994.
6. Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006.
MMWR Recomm Rep 2006;55:1-94.
7. French LM, Smaill FM. Antibiotic regimens for
endometritis after delivery. Cochrane Database
Syst Rev 2004;4:CD001067.
8. Lurie S, Rahamim E, Piper I, Golan A, Sadan
O. Total and differential leukocyte counts percentiles in normal pregnancy. Eur J Obstet Gynecol Reprod Biol 2008;136:16-9.
9. Blackwelder WC. Proving the null hypothesis in clinical trials. Control Clin Trials 1982;
3:345-53.
Research
301.e5